Sumeet Sud shares news about Pharmaceutical Companies License Agreement

Theravance Biopharma Ireland Limited, and Pfizer announced the companies have entered into a global license agreement for Theravance Biopharma’s preclinical program for skin-targeted, locally-acting pan-Janus kinase (JAK) inhibitor that can be rapidly metabolized. The compounds in this program target validated pro-inflammatory pathways and are specifically designed to process skin-selective activity with minimal systemic exposure.

https://www.sumeetsud.com/sumeet-sud-shares-news-about-global-license-agreement/

https://www.sumeetsud.com/tag/global/

https://www.sumeetsud.com/tag/license/

https://www.sumeetsud.com/tag/pfizer/

https://about.me/sumeetsud

https://www.xing.com/profile/Sumeet_Sud3

https://angel.co/sumeet-sud-1

https://sumeetsud.tumblr.com/